We use cookies to ensure that we give you the best experience on our website Learn more
Home
Saved research
Submission
Low rates of severe injection-site and systemic adverse events within 7 days post-vaccination with ZOSTAVAX™, a post hoc analysis of two pivotal phase 3 trials
Submitted
4 Views
0 Downloads
0 Saves
Presentation
Abstract
No abstract is available for this submission.
Datasets
No datasets are available for this submission.
License
No license information is available for this submission.
Company
Legal
Follow us
© Copyright 2021 Morressier GmbH. All rights reserved.